Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 394

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 394
---
holders of CERo in connection with the Business Combination from 4,651,704 shares
to 5,000,000 shares. Such number of shares is in addition to up to 1,200,000 shares issuable upon satisfaction of certain earn-out conditions
and 382,651 shares issuable upon exercise of rollover options or warrants.

On February 8, 2024, the Company held a special
meeting of stockholders (the “Fourth Special Meeting”). At the Fourth Special Meeting, the Company’s stockholders adopted
and approved (i) the Business Combination Agreement, pursuant to which Merger Sub merged with and into CERo, with CERo surviving as a
wholly-owned subsidiary of the Company and approved the Business Combination and the other transactions and ancillary documents contemplated
by and required for the Business Combination; (ii) on a non-binding advisory basis, certain changes to the Charter, including the name
change to CERo Therapeutics Holdings, Inc., share authorizations, and others; (iii) the issuance of Class A common stock to CERo stockholders
pursuant to the Business Combination Agreement; (iv) the election of five directors; and (v) the 2024 Equity Incentive Plan and the 2024
Employee Stock Purchase Plan, contingent of the consummation of the Business Combination.

In connection with the approval of the Business
Combination, holders of 671,285 shares of Class A common stock, exercised redemption rights. As a result, following satisfaction of such
redemptions, we had 5,563,297 shares of Class A common stock outstanding, of which (i) 82,047 were shares of Class A common stock issued
to the public in our IPO, which shares of Class A common stock were entitled to receive a pro rata portion of the remaining funds in
our Trust Account in connection with its initial business combination, a liquidation or certain other events, (ii) 4,596,250 were shares
of Class A common stock issued upon the conversion of an equal number of shares of our Class B common stock acquired by Sponsor prior
to our IPO, which shares of Class A common stock did not have redemption rights, and (iii) 885,000 were shares of Class A common stock
included in the private placement units acquired in the private placement by the Sponsor and other investors concurrent with our IPO,
which shares of Class A common stock did not have redemption rights.